Vincerx Pharma (NASDAQ:VINC – Get Free Report) is projected to announce its resultson Tuesday, November 10th. Analysts expect Vincerx Pharma to post earnings of ($8.00) per share for the quarter.
Vincerx Pharma Price Performance
Shares of NASDAQ VINC remained flat at $0.01 during mid-day trading on Tuesday. 14 shares of the stock were exchanged, compared to its average volume of 4,471. The stock has a market capitalization of $78,510.00, a P/E ratio of -0.00 and a beta of 1.46. The business has a 50-day simple moving average of $0.02 and a two-hundred day simple moving average of $0.01. Vincerx Pharma has a 1-year low of $0.00 and a 1-year high of $0.03.
Vincerx Pharma Company Profile
Vincerx Pharma, Inc is a clinical-stage biopharmaceutical company focused on developing targeted therapies for cancer. The company’s research programs are aimed primarily at hematologic malignancies, including leukemia and lymphoma, as well as other cancers with significant unmet treatment needs.
Vincerx has developed a pipeline that includes antibody-drug conjugates and small-molecule therapeutics. Its lead program, VIP943, is an investigational antibody-drug conjugate designed to target CD123, a protein expressed on several blood cancer cells.
Recommended Stories
- Five stocks we like better than Vincerx Pharma
- Alphabet’s Golden Dome Talks Could Open a New Market, But How Much Is at Stake?
- Tempus AI Surges on Earnings Beat, But Can the Rally Last?
- MicroVision Pivots: Mapping New Ground Beyond Auto
- Are the Fears Around Alphabet’s Search Slowdown Warranted?
Receive News & Ratings for Vincerx Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vincerx Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
